Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective | Nature Reviews Urology
Gender-specific Differences in Recurrence of Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis - European Urology Focus
Tumor Markers - Priority Health
JCI - Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer
Improving Early Detection and Clinical Management of Bladder Cancer
ABYNTEK | Tumor markers for cancer research: FAQS
Urinary peptide panel for prognostic assessment of bladder cancer relapse | Scientific Reports
Biological Markers in the Diagnosis of Recurrent Bladder Cancer
Life | Free Full-Text | Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers
Recurrent Bladder Cancer - CancerConnect
Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non–muscle-invasive bladder cancer and with low and intermediate EORTC-risk score | PLOS ONE
Cepheid | Bladder Cancer Monitor Biomarker Test - Xpert Bladder Cancer Monitor
Recurrent ZNF83-E293V Mutation Promotes Bladder Cancer Progression through the NF-κB Pathway via Transcriptional Dysregulation of S100A8: Molecular Therapy
Non muscle invasive bladder cancer treatment - WCRJ
Bladder Cancer Survival: The Importance of Early Detection | Cxbladder
Diagnostics | Free Full-Text | Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review
Artificial intelligence: A promising frontier in bladder cancer diagnosis and outcome prediction - ScienceDirect
Frontiers | Detecting and monitoring bladder cancer with exfoliated cells in urine
Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight - ScienceDirect
This policy documents the coverage determination for Urinary Tumor Markers for Bladder Cancer. The diagnosis of bladder cancer i
Dr. Peter Black | Urine Markers for Bladder Cancer | The Ideal Marker
Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study - eBioMedicine
Summary of urinary markers for bladder cancer | Download Table
Cancers | Free Full-Text | Noninvasive Urine-Based Tests to Diagnose or Detect Recurrence of Bladder Cancer
